drugset / Trial / NCT03780166

A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris

NCT03780166

Phase 2 Withdrawn Incyte Corporation
SequentialOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and tolerability of parsaclisib in participants with mild to moderate pemphigus vulgaris.

Timeline

Start
2019-03
Primary completion
2020-11
Completion
2020-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Parsaclisib Small molecule Oral

Indications